Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.

EBioMedicine - 1 Nov 2016

Zhang Yu-An, Zhou Yunyun, Luo Xin, Song Kai, Ma Xiaotu, Sathe Adwait, Girard Luc, Xiao Guanghua, Gazdar Adi F

Abstract excerpt

BACKGROUND: Diffuse gliomas, grades II and III, hereafter called lower-grade gliomas (LGG), have variable, difficult to predict clinical courses, resulting in multiple studies to identify prognostic biomarkers. The purpose of this study was to assess expression or methylation of the homeobox family gene SHOX2 as independent markers for LGG survival. METHODS: We downloaded publically available glioma datasets for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Kaplan-Meier Estimate
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Nucleic Acid

Share to Glioma

Share to Homeodomain Proteins

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 27840009
DOI: 10.1016/j.ebiom.2016.10.040
PMCID: PMC5264450

Genes

SHOX2
ATRX
MGMT
NES
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.PMID 27840009Read ↗

Downregulation of STOX1 is a novel prognostic biomarker for glioma patientsSemantic proximity Read ↗

The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse GliomasSemantic proximity Read ↗

Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade gliomaSemantic proximity Read ↗

Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade GliomasSemantic proximity Read ↗

The Role of ATRX in Glioma BiologySemantic proximity Read ↗

EZHIP's role in diffuse midline glioma: echoes of oncohistones?Semantic proximity Read ↗

TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomasSemantic proximity Read ↗

DNA methylation-regulated SNX20 overexpression correlates with poor prognosis, immune cell infiltration, and low-grade glioma progressionSemantic proximity Read ↗

In Lower-Grade Gliomas, the SPARC Family Exacerbates Prognosis by Influencing Immunity, Stemness, and Metabolism.Semantic proximity Read ↗

Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomasSemantic proximity Read ↗

TMEFF2 Promoter Hypermethylation Is an Unfavorable Prognostic Marker in GliomasSemantic proximity Read ↗

HOXDeRNA activates a cancerous transcription program and super-enhancers genome-wideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.